Students Research in Progress
Sunday, November 12, 2023
12:45 PM–02:15 PM
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) offer a novel mechanism of action for the treatment of different types of solid tumors and hematologic malignancies. Nebraska Medicine has multiple ICI on formulary with varying mechanisms of action, with all medications in this class restricted to use in the outpatient infusion center. However, pharmacy still receives requests from providers for inpatient administration of ICI treatment. Clinical trials that led to the approval of many of the ICIs only included patients with good performance status defined by Eastern Cooperative Oncology Group (ECOG) score = 1. This has led to a clinical controversy regarding the use of ICIs in patients with ECOG score = 2, including hospitalized patients. The goal of this study is to evaluate the inpatient utilization, clinical outcomes, and cost of ICI at Nebraska Medicine.
Research Question or Hypothesis: What are the clinical outcomes and cost implications of inpatient utilization of immune checkpoint inhibitors at Nebraska Medicine?
Study Design: Retrospective, single- center, observational chart review.
Methods: A retrospective chart review was conducted at Nebraska Medicine, a large academic medical center. Medication administration records were pulled from the electronic health record for adult patients (age = 19 years old) who received ICI treatment during an inpatient hospitalization between January 1, 2013, and June 15, 2023. Data analysis will be completed with primary outcome including 90-day mortality or admission to hospice. Secondary outcomes include hospital length of stay and time from inpatient ICI dose to death or hospice admission. A cost analysis will also be performed to evaluate the economic burden of administering ICIs in the inpatient setting.
Results: In-progress
Conclusion: In-progress
Presenting Author
Anna Rehberg B.A., PharmD Candidate 2024Nebraska Medicine
Authors
Lauren Bodhaine-Haywood PharmD, BCOP, BCPS
Nebraska Medicine
Ashley Bogus PharmD
Nebraska Medicine
Sara Kjerengtroen PharmD, BCPS
Nebraska Medicine